Tango Therapeutics announced significant board changes, including two resignations and the appointment of Sung Lee as Lead Independent Director, as it progresses towards late-stage clinical development. The company reported a Q1 2026 net loss of $45.5 million but maintains a strong cash position of $379.8 million, projected to fund operations into 2028. Tango is advancing its oncology programs, with a focus on vopimetostat for pancreatic cancer, and its stock currently holds a "Buy" rating from analysts with a $40.00 price target.

Invesco Ltd. has released its latest quarterly results, detailing movements in assets under management (AUM) and profitability. The article provides an overview of Invesco’s business model, key revenue drivers, competitive position, and risks for US investors, whose shares trade on the NYSE under the ticker IVZ. Invesco reported Q1 2025 adjusted earnings per share of $0.33 on $1.35 billion net revenue, with total AUM reaching $1.68 trillion by March 2025.

W.W. Grainger (GWW) reported strong Q1 2026 earnings, surpassing analyst EPS estimates with $11.65 and achieving a 10.1% increase in revenue. The industrial distributor also provided optimistic guidance for Q2 sales, projecting growth exceeding 12% on a daily organic constant currency basis. The company's stock has seen a 23.4% year-to-date rise, reflecting its leading position in the MRO market, driven by e-commerce penetration and operational efficiencies.

EBay has rejected a $56 billion takeover bid from GameStop, citing concerns over financing and the credibility and attractiveness of the proposal. EBay, which is four times larger than GameStop, emphasized its successful turnaround under CEO Jamie Iannone and its skepticism about the combined company achieving an investment-grade rating. GameStop CEO Ryan Cohen, who made the offer with a $20 billion debt financing commitment, may consider taking the bid directly to eBay shareholders.

NiSource Inc. (US65473P1057) reported strong Q1 2026 adjusted EPS of $1.06, an 8% year-over-year increase, and reaffirmed its full-year 2026 adjusted EPS guidance. The company also raised its long-term consolidated adjusted EPS compound annual growth rate outlook for 2023-2033 to 9%-10% from the previous 8%-9%, largely driven by new data center agreements. This signals confidence in its infrastructure growth strategy and its role in meeting increasing energy demands in the Midwest and Northeast US.

Becton Dickinson (BD), a global medical technology company, is a key player in medical devices and diagnostics, providing products like syringes and diagnostic systems. The company's business model is built around three segments: BD Medical, BD Life Sciences, and BD Interventional, generating steady revenue primarily from consumables. BD offers US investors exposure to defensive healthcare growth, with a strong dividend history and market leadership, though potential investors should consider regulatory risks and high debt from past mergers.

Garmin Ltd. (CH0114405324) shares dropped 2.23% to $236.97 on May 12, 2026, amid ongoing volatility on Nasdaq. The company, a leader in GPS technology and wearables, maintains a strong market position, especially in fitness, aviation, and marine segments, making it relevant for US investors. This decline follows recent price swings, with upcoming earnings expected around July 30, 2025.

Allegiant Travel Company has completed its acquisition of Sun Country Airlines, making Sun Country a wholly-owned subsidiary. Sun Country shareholders received $4.10 in cash plus 0.1557 Allegiant common shares for each share they held. This merger also triggered the termination of Sun Country's Tax Receivable Agreement, resulting in an $80.4 million payment to TRA holders and the eventual delisting of Sun Country stock from Nasdaq.

Argos Wealth Advisors LLC purchased 5,712 shares of Automatic Data Processing (ADP) in Q4, a new stake valued at $1.47 million, signaling institutional confidence in the human capital management solutions provider. ADP, a key player in the HCM sector and payroll services, continues to innovate with AI-powered solutions, maintaining its leadership position. The company offers stable dividends and a strong market presence, making it an attractive prospect for US investors seeking exposure to the resilient business services sector.

CVS Health Corp shares climbed over 5% after reporting strong Q1 2026 results, with adjusted EPS of $2.57 surpassing estimates by 18% and net income soaring 66% to nearly $3 billion. The company also raised its full-year 2026 adjusted EPS guidance, attributing the improvements to its Aetna, Caremark, and pharmacy operations. Revenues reached $100.4 billion, exceeding analyst estimates, and the medical benefit ratio improved significantly.